Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
38
Recruiting, any sponsor type, condition "glaucoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed636
38 trials
Showing 1 to 25, recently updated first.
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
Tavo BiotherapeuticsIndustry
NCT07913074 · 96 participants (planned) · Start Oct 23, 2026 · Primary completion Jun 30, 2027
Drug: Arm 1: TB0001 ophthalmic solution 0.9%; Arm 2: TB0001 ophthalmic solution 1.2% and 2 more · For: Primary Open - Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Sites: Glendale, California; Newport Beach, California; Lynchburg, Virginia
Brett KingAcademic, hospital or other
NCT07847073 · 13 participants (planned) · Start Oct 2026 · Primary completion Jan 2028
Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]; Timolol Maleate 0.25% Ophthalmic Solution · For: Open Angle Glaucoma (OAG); Glaucoma
Sites: Bloomington, Indiana
- Topical Insulin for GlaucomaRecruiting
Stanford UniversityAcademic, hospital or other
NCT05206877 · 52 participants (planned) · Start Apr 1, 2022 · Primary completion Dec 31, 2026
Drug: Insulin, 4 units; Insulin, 20 units and 4 more · For: Glaucoma
Sites: Palo Alto, California
- REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07675824 · 271 participants (planned) · Start Sep 8, 2026 · Primary completion Sep 14, 2029
Drug: REGN22530 · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Sites: Deerfield Beach, Florida
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
YS Life Science Co., Ltd.Industry
NCT07661329 · 600 participants (planned) · Start Jun 2, 2026 · Primary completion Nov 1, 2027
Drug: Bimatoprost ophthalmic solution 0.01% YSBP; bimatoprost ophthalmic solution 0.01% (Lumigan®) · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OH)
Sites: Beverly Hills, California; Inglewood, California; Newport Beach, California · 22 sites in all
- Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT07075718 · 110 participants (planned) · Start Jun 12, 2025 · Primary completion Mar 2028
Drug: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5% · For: Glaucoma
Sites: Grand Junction, Colorado; Oklahoma City, Oklahoma; El Paso, Texas
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.Industry
NCT07777861 · 90 participants (planned) · Start Mar 18, 2026 · Primary completion Oct 1, 2027
Drug: G01 Eye Drops 100μg/ml; G01 Eye Drops 200μg/ml and 1 more · For: Primary Open-Angle Glaucoma; Optic Nerve Injury
Sites: Beijing, China; Guangzhou, China; Shantou, China · 9 sites in all
University of Maryland, BaltimoreAcademic, hospital or other
NCT06993597 · 60 participants (planned) · Start Sep 1, 2025 · Primary completion Mar 2027
Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy; Beta Blocker · For: Glaucoma
Sites: Baltimore, Maryland
EyeD PharmaIndustry
NCT07036510 · 42 participants (planned) · Start Jun 12, 2025 · Primary completion Jan 2027
Drug: TimoD implant; Timolol eye drops 0.5% · For: Glaucoma; Ocular Hypertension
Sites: Panama City, Panama
Johns Hopkins UniversityAcademic, hospital or other
NCT07425535 · 30 participants (planned) · Start Jun 24, 2026 · Primary completion Mar 1, 2028
Drug: Latanoprost (0.005%) · For: Glaucoma
Sites: Baltimore, Maryland
University of Maryland, BaltimoreAcademic, hospital or other
NCT04401982 · 50 participants (planned) · Start Jul 2, 2026 · Primary completion Mar 17, 2027
Drug: Rocklatan (Netarsudil 0.02%/ latanoprost 0.005); Latanoprost (0.005%) · For: Ocular Hypertension; Suspect Glaucoma
Sites: Baltimore, Maryland; Columbia, Maryland; Silver Spring, Maryland · 4 sites in all
BayerBayer (BAYRY)
NCT04519619 · 480 participants (planned) · Start Nov 27, 2020 · Primary completion Jun 30, 2027
Drug: Aflibercept (Eylea, BAY86-5321) · For: Neovascular Glaucoma
Sites: Multiple Locations, Japan
- [KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
Kukje PharmaAcademic, hospital or other
NCT07662759 · 188 participants (planned) · Start Dec 9, 2025 · Primary completion Mar 2027
Drug: TFC-003; TFC-003-R1 and 1 more · For: Glaucoma Open-Angle Primary; Ocular Hypertension
Sites: Seongnam, South Korea
Indiana UniversityAcademic, hospital or other
NCT07588152 · 50 participants (planned) · Start Jun 5, 2026 · Primary completion Jun 2028
Drug: Netarsudil Ophthalmic Solution (Rhopressa) · For: Glaucoma; Ocular Hypertension
Sites: Bloomington, Indiana
- Travoprost Intraocular Implant + iStent InfinitePivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT06066645 · 150 participants (planned) · Start Sep 14, 2023 · Primary completion May 2027
Drug: Travoprost Intraocular Implant · For: Glaucoma, Open-Angle
Sites: Oklahoma City, Oklahoma
- Rocklatan vs Latanoprost Post-DSLTRecruiting
Eye Centers of Southeast TexasAcademic, hospital or other
NCT07465913 · 36 participants (planned) · Start May 14, 2026 · Primary completion May 6, 2027
Drug: Rocklatan 0.02%-0.005% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution · For: Glaucoma
Sites: Beaumont, Texas
- GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle GlaucomaRecruiting
IVIEW Therapeutics Inc.Industry
NCT06921317 · 6 participants (planned) · Start Nov 19, 2025 · Primary completion Dec 30, 2027
Drug: GVB-2001-high dose; GVB-2001-low dose · For: Primary Open-Angle Glaucoma (POAG)
Sites: Suzhou, China
Mayo ClinicAcademic, hospital or other
NCT07325240 · 30 participants (planned) · Start Nov 21, 2025 · Primary completion Jul 2027
Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution; Latanoprost 0.005% Ophthalmic Solution · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Rochester, Minnesota
Centre hospitalier de l'Université de Montréal (CHUM)Academic, hospital or other
NCT05180994 · 50 participants (planned) · Start May 1, 2022 · Primary completion Mar 1, 2027
Drug: Topical infliximab · For: Glaucoma Following Surgery
Sites: Montreal, Canada
- Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT07495852 · 510 participants (planned) · Start Feb 17, 2026 · Primary completion Jun 2028
Drug: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5% · For: Glaucoma
Sites: Dothan, Alabama
University of California, Los AngelesAcademic, hospital or other
NCT04354545 · 75 participants (planned) · Start Apr 1, 2021 · Primary completion Dec 1, 2026
Drug: Xiidra (Lifitegrast ophthalmic solution) 5% · For: Glaucoma; Ocular Surface Disease
Sites: Fountain Valley, California
- Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication UseRecruiting
University of MiamiAcademic, hospital or other
NCT07217678 · 20 participants (planned) · Start Feb 9, 2026 · Primary completion Jan 31, 2028
Drug: Durysta, Bimatoprost Intracameral Implant 10 µg · For: Glaucoma; Open-Angle Glaucoma; Ocular Hypertension and 1 more
Sites: Miami, Florida
Universiti Sains MalaysiaAcademic, hospital or other
NCT07396441 · 60 participants (planned) · Start Jan 15, 2026 · Primary completion May 15, 2026
Drug: Stingless bee honey (Kelulut) · For: Juvenile Open Angle Glaucoma; Dry Eye Disease (DED); Interleukin 6 and 2 more
Sites: Kota Bharu, Malaysia; Kuala Krai, Malaysia; Kubang Kerian, Malaysia · 4 sites in all
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
Huons Co., Ltd.Industry
NCT07335211 · 206 participants (planned) · Start Jan 2026 · Primary completion Nov 2027
Drug: HUC3-637; HUC3-637-R · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension
Sites: Seoul, South Korea
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.